TARA Protara Therapeutics, Inc.
Healthcare$4.68+0.00%OpenMarket Cap: $180.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.16
P/S
0.00
EV/EBITDA
-2.56
DCF Value
$1.03
FCF Yield
-33.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.7%
ROA
-33.0%
ROIC
-38.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-19.6M | $-17.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-19.1M | $-17.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-64.5M | $-57.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.8M | $-13.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-16.6M | $-15.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.1M | $-11.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-14.3M | $-12.8M | $— | — |
| FY null | $0.00 | NaN% | $-49.2M | $-44.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.3M | $-11.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.7M | $-9.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-11.9M | $-11.1M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-11.0M | $-10.2M | $-0.90 | — |